London: Tuesday, 29 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces the following blocklisting six monthly return:
1. Name of applicant:
Hutchison China MediTech Limited
2. Name of scheme:
Hutchison China MediTech Limited Share Option Scheme
3. Period of return:
From 29 June 2015 to 28 December 2015
4. Balance under scheme from previous return:
472,763 ordinary shares of US$1 each
5. The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
Nil
6. Number of securities issued/allotted under scheme during period: 18,750 ordinary shares of US$1 each
7. Balance under scheme not yet issued/allotted at end of the period:
454,013 ordinary shares of US$1 each
8. Number and class of securities originally listed and the date of admission:
2,560,606 ordinary shares of US$1 each admitted on 26 June 2007
9. Total number of securities in issue at the end of the period: 56,533,118 ordinary shares of US$1 each
Name of contact:
Christian Hogg
Address of contact:
21/F., Hutchison House, 10 Harcourt Road, Hong Kong
Telephone number of contact:
+852 2121 8200
Ends
Chi-Med
Christian Hogg, CEO
Telephone: +852 2121 8200
Panmure Gordon (UK) Limited
Telephone: +44 20 7886 2500
Richard Gray
Andrew Potts
Citigate Dewe Rogerson
Telephone: +44 20 7638 9571
Anthony Carlisle, Mobile: +44 7973 611 888
David Dible, Mobile: +44 7967 566 919
Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.